Jiangsu Aidea Pharmaceutical Co Ltd (688488) fair value: what the stock is really worth
As of Sep 30, 2026: fair value of Jiangsu Aidea Pharmaceutical Co Ltd ¥8.45, price ¥16.63, upside -49.2%, quality 61 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Jiangsu Aidea Pharmaceutical Co Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 3, 2026.
How to read this chart
60‑month range ¥6.66 – ¥26.59 · fair‑value band ¥7.98 – ¥8.78 · the ¥16.63 price screens above the ¥8.45 fair value. Dashed = 300-day average. As of Oct 3, 2026.
Follow Jiangsu Aidea Pharmaceutical Co in your weekly email
Every Wednesday you see whether Jiangsu Aidea Pharmaceutical Co is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Jiangsu Aidea Pharmaceutical Group Co., Ltd. develops, produces, and sells pharmaceutical products in China and internationally. It offers anti-HIV drugs and human-derived proteins.
Show more
Jiangsu Aidea Pharmaceutical Group Co., Ltd. develops, produces, and sells pharmaceutical products in China and internationally. It offers anti-HIV drugs and human-derived proteins. The company also provides anti-virus products, such as ainuovirine tablets; urinary protein products, including crude product/intermediate of ulinastatin, urinary kallidinogenase, and urokinase; sennae folium granules; and baicillus cereus tablets. It also exports its products. The company was formerly known as Jiangsu Aidea Pharmaceutical Co., Ltd. and changed its name to Jiangsu Aidea Pharmaceutical Group Co., Ltd. in July 2025. Jiangsu Aidea Pharmaceutical Group Co., Ltd. was founded in 2009 and is headquartered in Yangzhou, China.
Stock analysis
Jiangsu Aidea Pharmaceutical Co Ltd (688488) currently trades at ¥16.63, while our model-based Fair Value estimate is ¥8.45, 49.2% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of ¥2.64 per share, and 0 of the 8 models we run sit above the ¥16.63 price.
Bear case: the Earnings-Based group reads lowest at ¥1.23, and 8 of the 8 models stay below the price. Evidence for this calculation is medium.
Scenario range: ¥7.98 (bear) to ¥8.78 (bull), the price of ¥16.63 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 61/100 (solid quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Jiangsu Aidea Pharmaceutical Co Ltd reported revenue of 721M CNY in FY2025 versus 256M CNY in FY2021, a compound +29.6%/yr. Reported net income was −19.7M CNY in FY2025.
Key figures
Market cap 6.6B CNY (≈ $980M) · P/S ratio 9.68 · EPS (TTM) ¥−0.0200 · Dividend yield 0.3% · Net margin −2.7% · Return on equity 1.3% · Return on assets (EBIT) −4.6% · Operating margin 10.9%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 46 out of 100 (low confidence).
What moves the price
The share trades about 25% below its 52-week high and 43% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −49%, 688488 screens richer than that median.
Fair Value models
Bear ¥7.98Fair Value ¥8.45Bull ¥8.78
Price ¥16.63 · Upside -49.2%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.44/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+72.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+43.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+20.0%
Start year 2020 (pandemic)
Revenue growth 9 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.1%
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
17.1% (2020) → 6.6% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Compare Jiangsu Aidea Pharmaceutical Co Ltd with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 591 stocks
Beats the industry median on 8/12 measures
Overall it ranks above its industry peers.
Valuation
Quality Score61 · Top 25%
Fair Value upside−49.2% · Below median
Profitability
Return on equity (TTM)1.3% · Above median
Return on assets1.7% · Above median
Net margin (TTM)−0.8% · Below median
Operating margin (TTM)10.9% · Above median
Growth and dividend
Revenue growth14.1% · Above median
Dividend yield (TTM)0.3% · Bottom 25%
Balance sheet
Debt / equity0.07× · Above median
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/B1.02× · Cheaper than median
P/S (TTM)1.36× · Cheapest 25%
EV/EBITDA6.5× · Cheapest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)71· sector 0
PAST (return on equity)5· sector 0
HEALTH (low debt)96· sector 97
DIVIDEND (yield)6· sector 21
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Jiangsu Aidea Pharmaceutical Co Ltd Fair Value". https://www.fairvalue-calculator.com/stock/688488
Frequently asked questions
Is Jiangsu Aidea Pharmaceutical Co Ltd (688488) overvalued or undervalued?
As of Oct 3, 2026, our model estimates a fair value of ¥8.45 versus a price of ¥16.63, about −49% upside (overvalued).
What is the fair value of 688488?
Our model-based fair value for Jiangsu Aidea Pharmaceutical Co Ltd is ¥8.45 (as of Oct 3, 2026), built from audited fundamentals. The current price: ¥16.63.
What is the quality score of 688488?
Jiangsu Aidea Pharmaceutical Co Ltd has a Quality Score of 61/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Jiangsu Aidea Pharmaceutical Co Ltd (688488)?
Our model-based price target is the fair value of ¥8.45 (as of Oct 3, 2026) from 8 valuation models. Cautious scenario ¥7.98, optimistic scenario ¥8.78. It is a calculation from audited fundamentals, not an analyst target.
What is the Jiangsu Aidea Pharmaceutical Co Ltd stock forecast for 2026?
Our models put fair value at ¥8.45, about −49% upside versus a price of ¥16.63 (overvalued). Cautious scenario ¥7.98, optimistic scenario ¥8.78. The calculation is refreshed regularly with new filings.
What is the revenue of Jiangsu Aidea Pharmaceutical Co Ltd (688488)?
Jiangsu Aidea Pharmaceutical Co Ltd reported trailing-twelve-month revenue of about 723M CNY (latest available figure, as of Oct 3, 2026).
Does Jiangsu Aidea Pharmaceutical Co Ltd pay a dividend?
Jiangsu Aidea Pharmaceutical Co Ltd currently shows a dividend yield of about 0.30% relative to its recent price (as of Oct 3, 2026).
What is the intrinsic value of Jiangsu Aidea Pharmaceutical Co Ltd (688488)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Jiangsu Aidea Pharmaceutical Co Ltd it is ¥8.45 per share (as of Oct 3, 2026), against a price of ¥16.63. It is the blended result of 8 valuation models (cash flow, earnings, asset, dividend).
Is Jiangsu Aidea Pharmaceutical Co Ltd stock overvalued or undervalued in 2026?
As of Oct 3, 2026, 688488 trades above its calculated fair value: price ¥16.63, fair value ¥8.45, a gap of about −49% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 688488?
No. The price is what the market pays today (¥16.63); the fair value is what the company's own numbers justify (¥8.45). For Jiangsu Aidea Pharmaceutical Co Ltd the two are ¥8.18 per share apart. That gap is exactly why we show both numbers side by side.
How much is Jiangsu Aidea Pharmaceutical Co Ltd worth?
The market values Jiangsu Aidea Pharmaceutical Co Ltd at about 6.6B CNY (market capitalisation, as of Oct 3, 2026). Per share that is ¥16.63; our models calculate a fair value of ¥8.45 per share.
What do the bullish and bearish scenarios say about 688488?
Our models span a range for Jiangsu Aidea Pharmaceutical Co Ltd: cautious scenario ¥7.98, base ¥8.45, optimistic ¥8.78 per share (as of Oct 3, 2026, price ¥16.63). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Jiangsu Aidea Pharmaceutical Co Ltd (688488)?
Balance-sheet figures for Jiangsu Aidea Pharmaceutical Co Ltd (as of Oct 3, 2026): return on equity 1.3%, debt of 0.07 per unit of equity. They feed the Quality Score of 61/100, which measures business quality independently of the share price.
How far is 688488 from its 52-week high?
Jiangsu Aidea Pharmaceutical Co Ltd trades at ¥16.63, about 25% below its 52-week high of ¥22.16 and 43% above the low of ¥11.59 (as of Sep 30, 2026). Distance from the high says nothing about value: that is what the fair value of ¥8.45 is for.
Which stocks are comparable to Jiangsu Aidea Pharmaceutical Co Ltd?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Jiangsu Aidea Pharmaceutical Co Ltd stock attractive at the current price?
The data as of Oct 3, 2026: price ¥16.63, calculated fair value ¥8.45 (−49%), Quality Score 61/100, from 8 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 688488 calculated?
We run Jiangsu Aidea Pharmaceutical Co Ltd through 8 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ¥8.45, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.9 % above its aggregate fair value. Jiangsu Aidea Pharmaceutical Co Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Jiangsu Aidea Pharmaceutical Co Ltd (688488)?
The closing price on Sep 30, 2026 was ¥16.63. Our model-based fair value is ¥8.45, about −49% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Jiangsu Aidea Pharmaceutical Co Ltd right now?
The price sits above even our optimistic bull case (¥8.78). The favourable scenario is already priced in. Solid but not exceptional quality (61/100) and above fair value, neither a clear bargain nor a standout compounder. The models converge in a tight band (¥7.98 to ¥8.78), unusually little disagreement for a valuation.
Key figures of Jiangsu Aidea Pharmaceutical Co Ltd
How large is the market capitalisation of Jiangsu Aidea Pharmaceutical Co Ltd (688488)?
The market capitalisation of Jiangsu Aidea Pharmaceutical Co Ltd is 6.6B CNY (≈ $980M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Jiangsu Aidea Pharmaceutical Co Ltd (688488)?
The price-to-sales ratio of Jiangsu Aidea Pharmaceutical Co Ltd is 9.68 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Jiangsu Aidea Pharmaceutical Co Ltd (688488)?
Earnings per share at Jiangsu Aidea Pharmaceutical Co Ltd are ¥−0.0200. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Jiangsu Aidea Pharmaceutical Co Ltd (688488)?
The dividend yield of Jiangsu Aidea Pharmaceutical Co Ltd is 0.3%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Jiangsu Aidea Pharmaceutical Co Ltd (688488)?
The net margin of Jiangsu Aidea Pharmaceutical Co Ltd is −2.7% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Jiangsu Aidea Pharmaceutical Co Ltd (688488)?
The return on equity (ROE) of Jiangsu Aidea Pharmaceutical Co Ltd is 1.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Jiangsu Aidea Pharmaceutical Co Ltd (688488)?
On an EBIT basis the return on assets of Jiangsu Aidea Pharmaceutical Co Ltd is −4.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Jiangsu Aidea Pharmaceutical Co Ltd (688488)?
The operating margin of Jiangsu Aidea Pharmaceutical Co Ltd is 10.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Jiangsu Aidea Pharmaceutical Co Ltd (688488)?
Revenue at Jiangsu Aidea Pharmaceutical Co Ltd is growing +14.1% versus a year earlier (3y avg +43.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Jiangsu Aidea Pharmaceutical Co Ltd (688488)?
Earnings per share at Jiangsu Aidea Pharmaceutical Co Ltd are growing −50.0% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Jiangsu Aidea Pharmaceutical Co Ltd (688488) generate?
The free cash flow of Jiangsu Aidea Pharmaceutical Co Ltd is −30.3M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Jiangsu Aidea Pharmaceutical Co Ltd (688488) carry?
The net debt of Jiangsu Aidea Pharmaceutical Co Ltd is 65.8M CNY (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Jiangsu Aidea Pharmaceutical Co Ltd in the live analysis
One click puts Jiangsu Aidea Pharmaceutical Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
